In the past years the development of computer technologies and electronics has undergone significant changes. New products and services have begun to establish in different fields of the industry.
But how will the newly gained knowledge and the associated opportunities transfer to the conservative pharma industry? How will the manufacturing process itself, the supply chain as a whole or the patient usability of the product change under this influence?
Currently a change in thinking seems to be taking place in our industry, specifically with regards to the use of smart data, machine learning and wireless connectivity. It has become increasingly indispensable for companies to provide expertise in these areas. Simultaneously the technological advancements are reflected in novel regulatory guidelines, for example in the area of serialization. Additionally, digital platforms providing therapy support to patients are on the rise, involving wearables and connected drug delivery devices systems.
Yet technology alone is not sufficient – value is added only by implementing practical applications and solutions. Often this is only possible with a strong partner.